News | April 03, 2026
ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The decision is based on the phase 3 DESTINY-Breast11 trial
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
Subscribe To Our Newsletter & Stay Updated
